Belite Bio, Inc BLTE
157.69 USD +3.50 (+2.27%)
At closeNov 9, 2026, 4:00 PM EST
157.69 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
152.99 Day range 159.49
102.00 52-week range 200.00
- YTD
- -1.42%
- 1 year
- +39.31%
News
globenewswire.com Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics…
benzinga.com Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19 Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
benzinga.com Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1 Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have- benzinga.com Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234 Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $220 to $234.
benzinga.com HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245 HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $214 to $245.- benzinga.com Belite Bio Submits Japanese New Drug Application For Tinlarebant In Stargardt Disease Type 1 Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and…
benzinga.com Why Is Belite Bio Stock Soaring Friday? Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.
benzinga.com This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.
benzinga.com Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303 Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.
benzinga.com Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206 Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $201 to $206.
benzinga.com Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270 Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $266 to $270.
benzinga.com Full Transcript: Belite Bio Q2 2026 Earnings Call Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…- benzinga.com Belite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) Estimate Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.79) by 31.65 percent. This is a 8 percent decrease over losses of $(0.50) per…
benzinga.com CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.
benzinga.com HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214 HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $200 to $214.
benzinga.com Why Is Belite Bio Stock Gaining Monday? Belite Bio (BLTE) stock jumps 3% on positive Phase 3 DRAGON trial data for its Stargardt disease drug candidate tinlarebant.
benzinga.com Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In Montréal Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growthPresentation to…
benzinga.com HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
benzinga.com Full Transcript: Belite Bio Q1 2026 Earnings Call - benzinga.com Mizuho Maintains Outperform on Belite Bio, Lowers Price Target to $215 Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and lowers the price target from $223 to $215.
benzinga.com HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
benzinga.com Earnings Scheduled For May 20, 2026 - benzinga.com Belite Bio Q1 EPS $(0.45) Beats $(0.63) Estimate Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is unchanged from the same period last year.
- benzinga.com Belite Bio's Tinlarebant Receives Orphan Drug Status From Swiss Agency For Therapeutic Products To Treat Stargardt Disease Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have…
- benzinga.com Belite Bio To Present Topline Data From Phase 3 DRAGON Study Of Stargardt Disease Type 1 Treatment At 27th Fundus Disease Forum And International Retinal Symposium Belite Bio, Inc. (NASDAQ:BLTE), ("Belite Bio®" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
- benzinga.com Belite Bio Initiates Rolling Submission Of New Drug Application To FDA For Tinlarebant Oral Therapy To Treat Stargardt Disease Type 1 Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $200 HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $185 to $200.
- benzinga.com Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $201 Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $191 to $201.
- benzinga.com Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $266 Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $200 to $266.
- benzinga.com Belite Bio Q4 EPS $(0.70) Misses $(0.54) Estimate Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.54) by 29.15 percent. This is a 118.75 percent decrease over losses of…
- benzinga.com Earnings Scheduled For March 2, 2026
benzinga.com Exploring Belite Bio's Earnings Expectations - benzinga.com HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $185 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $185 price target.
benzinga.com This Compass Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - benzinga.com B of A Securities Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $195 B of A Securities analyst Tazeen Ahmad initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $195.
- benzinga.com Morgan Stanley Initiates Coverage On Belite Bio with Overweight Rating, Announces Price Target of $191 Morgan Stanley analyst Judah Frommer initiates coverage on Belite Bio (NASDAQ:BLTE) with a Overweight rating and announces Price Target of $191.
- benzinga.com Mizuho Upgrades Belite Bio to Outperform, Raises Price Target to $194 Mizuho analyst Graig Suvannavejh upgrades Belite Bio (NASDAQ:BLTE) from Neutral to Outperform and raises the price target from $105 to $194.
- benzinga.com Belite Bio Announces Proposed Underwritten Public Offering Of American Depositary Shares; No Terms Disclosed Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have…
- benzinga.com HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $185 HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $98 to $185.
benzinga.com Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease Belite Bio's Tinlarebant cut lesion growth in a pivotal Stargardt Phase 3 trial, showing strong efficacy and a consistent safety profile.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Belite Bio Unveils Phase 3 DRAGON Trial Results Showing Tinlarebant Significantly Reduces Stargardt Disease Lesion Growth Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met…
benzinga.com Alibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday - benzinga.com Cantor Fitzgerald Assumes Belite Bio at Overweight, Announces Price Target of $154 Cantor Fitzgerald analyst Steve Seedhouse assumes Belite Bio (NASDAQ:BLTE) with a Overweight rating and announces Price Target of $154.
- benzinga.com Mizuho Initiates Coverage On Belite Bio with Neutral Rating, Announces Price Target of $105 Mizuho analyst Graig Suvannavejh initiates coverage on Belite Bio (NASDAQ:BLTE) with a Neutral rating and announces Price Target of $105.
- benzinga.com Belite Bio Q3 EPS $(0.65) Misses $(0.45) Estimate Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.45) by 44.44 percent. This is a 132.14 percent decrease over losses of…
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com Earnings Outlook For Belite Bio